EICHOR
● Active Not Recruiting
The REPLACE Registry for Cholbam® (Cholic Acid)
Condition: Bile Acid Synthesis Disorders · Sponsor: Mirum Pharmaceuticals, Inc.
About this study
This is a prospective, observational, non-interventional patient registry study designed to document product safety and effectiveness outcomes for 10 years in patients treated with Cholbam, including those who have been using Cholbam for at least 30 days (existing users) and those who are first-time initiators of Cholbam.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (24)
| University of Alabama Birmingham | Birmingham, Alabama, United States | — |
| Stanford School of Medicine | Palo Alto, California, United States | — |
| UC San Francisco | San Francisco, California, United States | — |
| Kidz Pediatric Multispecialty Group | Hollywood, Florida, United States | — |
| Nemours duPont Pediatrics Specialty Clinic | Jacksonville, Florida, United States | — |
| Nicklaus Children's Hospital | Miami, Florida, United States | — |
| Children's Healthcare of Atlanta | Atlanta, Georgia, United States | — |
| Children's Center For Digestive Health | Atlanta, Georgia, United States | — |
| The Community Health Clinic | Topeka, Indiana, United States | — |
| Ochsner Hospital for Children | New Orleans, Louisiana, United States | — |
| University of Minnesota | Minneapolis, Minnesota, United States | — |
| Mayo Clinic | Rochester, Minnesota, United States | — |
+ 12 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.